Cognition in hepatitis C patients treated with pegylated interferon

References

• Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 53–63
   Web of Science ®Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New Engl J Med 1998; 339: 1493–1499
   PubMed Web of Science ®Google Scholar
• Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000; 157: 867–876
   PubMed Web of Science ®Google Scholar
• Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26(3 Suppl 1)112–121S
   PubMed Web of Science ®Google Scholar
• Eberhardt G. Flimmerfrequenz-Analysator. Automatische Messmethode. Version 3.00. Dr G. Schuhfried GmbH, MödlingAustria 1994
   Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders SCID I: clinical version 2.0. Rev. Biometrics Research Department, New York State Psychiatric Institute, New York 1998
   Google Scholar
• Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000; 18: 107–116
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Bieliauskas LA, Back-Madruga C, et al. HALT-C Trial Group. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol 2005; 43: 614–622
   PubMed Web of Science ®Google Scholar
• Forton DM, Taylor-Robinson SD, Thomas HC. Central nervous system changes in hepatitis C virus infection. Eur J Gastroenterol Hepatol 2006; 18: 333–338
   PubMed Web of Science ®Google Scholar
• Goldman HH, Skodal AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992; 149: 1148–1156
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–55
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 35: 440–446
   PubMed Web of Science ®Google Scholar
• Hilsabeck RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W. Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc 2005; 11: 16–22
   PubMed Web of Science ®Google Scholar
• Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 64: 708–714
   PubMed Web of Science ®Google Scholar
• Kraus MR, Schäfer A, Csef H, Scheurlen M. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 2005a; 11: 1769–1774
   PubMed Web of Science ®Google Scholar
• Kraus MR, Schäfer A, Wissmann S, Reimer P, Scheurlen M. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin Pharmacol Ther 2005b; 77: 90–100
   PubMed Web of Science ®Google Scholar
• Laux L, Glanzmann P, Schaffner P, Spielberger CD. Das State-Trait-Angstinventar. Beltz, Weinheim 1981
   Google Scholar
• Lehrl S. Mehrfachwahl-Wortschatz-Intelligenztest. B-Version. Straube, Erlangen 1977
   Google Scholar
• Lieb K, Engelbrecht MA, Gut O, et al. Cognitive impairment in patients with chronic hepatitis treated with interferon alpah (IFNalpha): results from a prospective study. Eur Psychiatry 2006; 21: 204–210
   PubMed Web of Science ®Google Scholar
• Licinio J, Kling MA, Hauser P. Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol 1998; 25: 30–38
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965
   PubMed Web of Science ®Google Scholar
• McAndrews MP, Farcnik K, Carlen P, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801–808
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Engl J Med 1998; 339: 1485–1492
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J Psychiatry 1979; 134: 382–389
   PubMed Web of Science ®Google Scholar
• Norusis MJ. SPSS 10.0 Guide to Data Analysis. Prentice Hall, Englewood Cliffs, NJ 2000
   Google Scholar
• Raisson CL, Borisov AS, Broadwell DS, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66: 41–48
   PubMedGoogle Scholar
• Reichenberg A, Gorman JM, Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 2005; 19(Suppl 3)S174–178
   Web of Science ®Google Scholar
• Reitan RM. The relation of the trail making test to organic brain damage. J Cons Psychol 1958; 19: 393–394
   Google Scholar
• Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147: 1577–1580
   PubMed Web of Science ®Google Scholar
• Smith A, Tyrrell D, Coyle K, Higgins P. Effects of interferon alpha on performance in man: a preliminary report. Psychopharmacology (Berlin) 1988; 96: 414–416
   PubMed Web of Science ®Google Scholar
• Smith JM, Misiak H. Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects – a review. Psychopharmacology 1976; 47: 175–182
   PubMed Web of Science ®Google Scholar
• Vienna test system (WINWTS). 1999. Version 4.50. MödlingAustria: Dr G. Schuhfried GmbH.
   Google Scholar
• Weissenborn, K, Ennen, JC, Bokemeyer, M, , et al. 2006. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut, Epub ahead of print.
   PubMedGoogle Scholar
• Zeuzem S, Heathcote JE, Martin N, Nieforth K, Modi M. Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opin Invest Drugs 2001; 10: 2201–2213
   PubMed Web of Science ®Google Scholar